Want to see HYFT full AI Analyst Report?
Top Page
MindWalk Holdings
(NASDAQ:HYFT)
Select Model
Select Model
Rating:52Neutral
Price Target:
$1.50
▲(5.63% Upside)
Action:Reiterated
Date:10/06/26
The score is held back primarily by weak financial performance: large ongoing losses, significant free-cash-flow burn, and substantial equity erosion despite improving gross margins. Technicals are moderately supportive with the stock trading above major moving averages and mild positive momentum. The latest earnings call adds some upside from improving growth/margins and non-dilutive financing, but uncertainty around contract timing and continued losses limit the overall rating.
Positive Factors
Revenue growth and margin expansion
Consecutive year-over-year growth combined with higher gross margin indicates improving commercial traction and better economics per dollar of revenue. If sustained, this combination can provide greater operating leverage and support investment in the company’s platform transition over the next several quarters.
Negative Factors
Severe losses and cash burn
Persistent operating losses are translating into substantial cash outflows rather than remaining primarily non-cash accounting charges. Continued burn can consume available liquidity, increase reliance on external financing, and restrict the company’s ability to fund ReefIQ, internal pipeline work, and commercial expansion independently.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and margin expansion
Consecutive year-over-year growth combined with higher gross margin indicates improving commercial traction and better economics per dollar of revenue. If sustained, this combination can provide greater operating leverage and support investment in the company’s platform transition over the next several quarters.
Read all positive factors
MindWalk Holdings Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down MindWalk Holdings’ revenue by region, showing where demand is strongest, which markets are driving growth, and how exposed the company is to local economic or regulatory risks.
Breaks down MindWalk Holdings’ revenue by region, showing where demand is strongest, which markets are driving growth, and how exposed the company is to local economic or regulatory risks.
Data provided by:
The Fly
The FlyMindWalk Holdings (HYFT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$65.96M
Dividend YieldN/A
Average Volume (3M)265.67K
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue Growth-26.89%
EPS Growth56.50%
CountryUS
Employees76
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.37
Shares Outstanding47,111,668
10 Day Avg. Volume390,314
30 Day Avg. Volume265,672
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)6.39
Price to Sales (P/S)4.89
P/FCF Ratio-5.92
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue3.55
Enterprise Value/Gross Profit5.84
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$4.33Price Target Upside205.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$18.46M
MindWalk Holdings Business Overview & Revenue Model
Company Description
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the ident...
MindWalk Holdings Earnings Call Summary
Earnings Call Date:Sep 14, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Dec 10, 2026
Earnings Call Sentiment Positive
The call was predominantly positive, supported by 21% year-over-year revenue growth, five consecutive quarters of year-over-year growth, gross margin expansion to 59%, progress launching ReefIQ, a strong pharmaceutical customer base, clinical validation, platform partnership traction, and a USD 30 million non-dilutive financing commitment. The main negative factors were the increased $6.1 million loss, higher operating expenses, a lower cash balance, uncertain and potentially lumpy timing for ReefIQ revenue, and the absence of announced enterprise contracts or specific closing timelines.Positive Updates
Revenue Growth Continued
First-quarter fiscal year 2027 revenue was $3.8 million versus $3.2 million in the first quarter of fiscal year 2026, an improvement of approximately $673,000 or 21%. This marked 5 quarters of consecutive year-over-year revenue growth.
Negative Updates
Net Loss Increased
Net loss and loss from continuing operations was $6.1 million in the first quarter of fiscal year 2027, compared with a $4.1 million loss from continuing operations in the first quarter of fiscal year 2026. The prior year's overall net loss was $3 million, including $1.1 million of income from discontinued operations.
Read all updates
Q1-2027 Updates
Positive
Negative
Revenue Growth Continued
First-quarter fiscal year 2027 revenue was $3.8 million versus $3.2 million in the first quarter of fiscal year 2026, an improvement of approximately $673,000 or 21%. This marked 5 quarters of consecutive year-over-year revenue growth.
Read all positive updates
Company Guidance
Management said initial ReefIQ agreements are “probably going to be relatively lumpy,” milestone based, with engineering efforts “at the outset” before becoming annual recurring revenue; revenue is expected to be “a little lumpy” and “hard to forecast,” depending on how quickly MindWalk gets adoption of ReefIQ, and management declined to provide an “exact more specific timeline” for closing agreements. The USD 30 million unsecured revolving credit facility has 60 days to complete the credit agreement, after which capital will be drawn “as we need it and as we need liquidity,” while the company still has cash runway; the facility carries a fixed 7% rate. Management said roughly 80% of the current funnel by value is structured as platform partnerships, the company has relationships with 19 of the top 20 global pharmaceutical companies, 10 molecules are in active Phase I through Phase III trials, 4 are first-in-class, and interested parties in ring-fenced Cayman assets are “probably 90%, 95% of the way in” on legal and tax planning.MindWalk Holdings Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
42
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.19M | 15.32M | 24.52M | 24.52M | 20.66M | 19.36M |
| Gross Profit | 9.84M | 9.01M | 13.55M | 12.05M | 11.56M | 10.98M |
| EBITDA | -16.67M | -13.13M | -28.86M | -22.95M | -21.04M | -11.99M |
| Net Income | -13.24M | -13.74M | -30.23M | -26.11M | -26.56M | -16.71M |
Balance Sheet | ||||||
| Total Assets | 17.33M | 21.34M | 44.44M | 59.99M | 77.81M | 93.49M |
| Cash, Cash Equivalents and Short-Term Investments | 7.63M | 11.33M | 10.66M | 3.46M | 8.28M | 29.96M |
| Total Debt | 3.49M | 3.52M | 13.40M | 13.68M | 14.27M | 2.77M |
| Total Liabilities | 10.42M | 9.61M | 20.82M | 26.07M | 20.01M | 18.36M |
| Stockholders Equity | 6.91M | 11.73M | 23.63M | 33.92M | 57.80M | 75.28M |
Cash Flow | ||||||
| Free Cash Flow | -12.61M | -12.66M | -7.21M | -5.64M | -21.33M | -11.18M |
| Operating Cash Flow | -12.41M | -12.27M | -6.41M | -4.25M | -19.83M | -9.92M |
| Investing Cash Flow | 13.99M | 13.34M | -799.00K | -1.56M | -1.97M | -5.21M |
| Financing Cash Flow | 1.06M | 113.23K | 14.89M | 1.02M | -621.00K | 2.88M |
MindWalk Holdings Technical Analysis
Positive
1.42
Price Trends
1.37
Positive
1.45
Positive
1.46
Positive
Market Momentum
0.03
Negative
55.01
Neutral
32.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYFT, the sentiment is Positive. The current price of 1.42 is above the 20-day moving average (MA) of 1.40, above the 50-day MA of 1.37, and below the 200-day MA of 1.46, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 55.01 is Neutral, neither overbought nor oversold. The STOCH value of 32.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYFT.
MindWalk Holdings Risk Analysis
MindWalk Holdings disclosed 51 risk factors in its most recent earnings report. MindWalk Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Market and industry data, market size estimates and growth forecasts that we reference are subject to uncertainty and may prove to be inaccurate. Q1, 2026
2.
Our shift toward a more software-led model, while continuing to operate wet lab services, may disrupt our operations, service quality and client relationships. Q1, 2026
3.
We may not successfully execute our software-led strategy, including the commercialization and scaling of LensAI, which could adversely affect our growth, operating results and financial condition. Q1, 2026
MindWalk Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $106.47M | -0.95 | -78.11% | ― | ― | 9.38% | |
52 Neutral | $65.96M | -5.76 | -144.31% | ― | -26.89% | 56.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $47.71M | -1.35 | -166.98% | ― | ― | 55.37% | |
49 Neutral | $374.41M | -3.65 | -47.52% | ― | ― | 57.98% |
* Healthcare Sector Average
HYFT
MindWalk Holdings
1.48
-0.32
-17.78%
XBIT
XBiotech
2.16
-0.35
-13.94%
RLMD
Relmada Therapeutics
3.36
1.43
74.09%
PMVP
PMV Pharmaceuticals
1.35
-0.07
-4.93%
HOWL
Werewolf Therapeutics
0.99
-0.68
-40.66%
ESLA
Estrella Immunopharma
0.31
-1.37
-81.31%
MindWalk Holdings Corporate Events
MindWalk Holdings Files Form 6-K, Updates Investors on Q2 2026 Results and Key Risks
Sep 14, 2026
On September 14, 2026, MindWalk Holdings filed a Form 6-K in the U.S., incorporating its Management’s Discussion and Analysis and condensed interim consolidated financial statements for the three months ended July 31, 2026 and 2025 into exis...
MindWalk Posts Q1 Revenue Growth and Secures US$30 Million Credit Facility to Scale ReefIQ
Sep 14, 2026
MindWalk reported fiscal first-quarter 2027 results on September 14, 2026, for the period ended July 31, 2026, highlighting a strategic shift toward recurring platform revenue. Revenue rose 21% year over year to $3.8 million and gross margin expan...
MindWalk Secures US$30 Million Non-Dilutive Credit Facility to Accelerate Biologics and AI Expansion
Sep 14, 2026
On September 14, 2026, MindWalk Holdings announced a binding commitment with Sanabil (Cayman) for a senior unsecured revolving credit facility of up to US$30 million. The funding is earmarked to support MindWalk’s biologics programs, commerc...
MindWalk Unveils First Public ReefIQ Demo on AMD Instinct at Advancing AI 2026
Jul 23, 2026
On July 23, 2026, MindWalk Holdings Corp. used AMD’s Advancing AI 2026 event in San Francisco to debut the first public demonstration of ReefIQ, its biological context layer for AI-driven drug discovery, running on AMD Instinct accelerators....
MindWalk Holdings Posts 46% Revenue Surge as Pivot to Bio-Native AI Infrastructure Takes Hold
Jul 22, 2026
For the fiscal year ended April 30, 2026, MindWalk Holdings reported a 46% jump in revenue to $15.6 million, gross margin expansion to nearly 59%, and a net loss reduced by more than half to $13.9 million, as the company completed its pivot from b...
MindWalk Holdings Sets July 22, 2026 Date to Report FY 2026 Results and Business Highlights
Jul 13, 2026
MindWalk Holdings Corp., a Bio-Native AI specialist serving the life sciences sector, has developed a proprietary HYFT technology that encodes 660 million biological patterns and 25 billion relationships, forming the foundation for its ReefIQ data...
MindWalk Holdings Added to Russell 3000E Index, Boosting Bio-Native AI Visibility
Jul 6, 2026
MindWalk Holdings Corp. said it has been added to the Russell 3000E Index following the FTSE Russell U.S. index reconstitution that took effect after the market close on June 26, 2026. Membership, reconfirmed in data published June 29, 2026, place...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.